Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation

Bone

Volumn 51, Issue 4, 2012, Pages 729-736

  Tomida, Kodo ^a   Hamano, Takayuki ^b   Ichimaru, Naotsugu ^b   Fujii, Naohiko ^c   Matsui, Isao ^b   Nonomura, Norio ^b,d   Tsubakihara, Yoshiharu ^b   Rakugi, Hiromi ^b   Takahara, Shiro ^b   Isaka, Yoshitaka ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Hyogo Prefectural Nishinomiya Hospital   (Japan)

^d NONE   (Japan)

Author keywords

Fibroblast growth factor 23 (FGF23); Persistent hyperparathyroidism; Renal transplantation; Tubular reabsorption of phosphate normalized for the glomerular filtration rate (TmP GFR); Uremic memory

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM;

EID: 84865624538     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.027     Document Type: Article

References (46)

1. Ambuhl P.M., Meier D., Wolf B., Dydak U., Boesiger P., Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999, 34:875-883.
2. Bhan I., Shah A., Holmes J., Isakova T., Gutierrez O., Burnett S.A., et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'?. Kidney Int 2006, 70:1486-1494.
3. Evenepoel P., Meijers B.K., de Jonge H., Naesens M., Bammens B., Claes K., et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008, 3:1829-1836.
4. Evenepoel P., Naesens M., Claes K., Kuypers D., Vanrenterghem Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007, 7:1193-1200.
5. Baum M., Schiavi S., Dwarakanath V., Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005, 68:1148-1153.
6. Tomoe Y., Segawa H., Shiozawa K., Kaneko I., Tominaga R., Hanabusa E., et al. Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice. Am J Physiol Renal Physiol Jun 2010, 298(6):F1341-F1350.
7. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004, 314:409-414.
8. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
9. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201.
10. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, S1-S130.
11. Bijvoet O.L., Morgan D.B., Fourman P. The assessment of phosphate reabsorption. Clin Chim Acta 1969, 26:15-24.
12. Payne R.B. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 1998, 35(Pt 2):201-206.
13. Tomida K., Hamano T., Mikami S., Fujii N., Okada N., Matsui I., et al. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 2009, 44:678-683.
14. Tanaka H., Hamano T., Fujii N., Tomida K., Matsui I., Mikami S., et al. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009, 45:949-955.
15. Payne R.B., Little A.J., Williams R.B., Milner J.R. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973, 4:643-646.
16. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
17. Barth J.H., Jones R.G., Payne R.B. Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram. Ann Clin Biochem 2000, 37(Pt 1):79-81.
18. Uemura H., Irahara M., Yoneda N., Yasui T., Genjida K., Miyamoto K.I., et al. Close correlation between estrogen treatment and renal phosphate reabsorption capacity. J Clin Endocrinol Metab 2000, 85:1215-1219.
19. Faroqui S., Levi M., Soleimani M., Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int 2008, 73:1141-1150.
20. Carrillo-Lopez N., Roman-Garcia P., Rodriguez-Rebollar A., Fernandez-Martin J.L., Naves-Diaz M., Cannata-Andia J.B. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 2009, 20:2009-2017.
21. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
22. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
23. Tominaga Y., Tanaka Y., Sato K., Nagasaka T., Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997, 13:78-86.
24. Wallfelt C.H., Larsson R., Gylfe E., Ljunghall S., Rastad J., Akerstrom G. Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparathyroidism: implication for parathyroid autotransplantation. World J Surg 1988, 12:431-438.
25. Kifor O., Moore F.D., Wang P., Goldstein M., Vassilev P., Kifor I., et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81:1598-1606.
26. Gogusev J., Duchambon P., Hory B., Giovannini M., Goureau Y., Sarfati E., et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997, 51:328-336.
27. Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993, 92:1436-1443.
28. Taniguchi M., Tokumoto M., Matsuo D., Motoyama K., Sugitani A., Kuroki S., et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int 2006, 70:363-370.
29. Evenepoel P., Kuypers D., Maes B., Messiaen T., Vanrenterghem Y. Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. Acta Otorhinolaryngol Belg 2001, 55:177-186.
30. Douthat W.G., Orozco S.E., Maino P., Cardozo G., de Arteaga J., de la Fuente J., et al. Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism. Transpl Int 2007, 20:1031-1035.
31. Malyszko J., Lebkowska U., Wolczynski S., Malyszko J.S., Mysliwiec M. Parathyroid gland sonography in relation to markers of bone metabolism in kidney transplant recipients. Transplant Proc 2002, 34:593-595.
32. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001, 280:1015-1020.
33. Komaba H., Koizumi M., Fukagawa M. Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future?. Kidney Int 2010, 78:953-955.
34. Krajisnik T., Olauson H., Mirza M.A., Hellman P., Akerstrom G., Westin G., et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010, 78:1024-1032.
35. Querings K., Girndt M., Geisel J., Georg T., Tilgen W., Reichrath J. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 2006, 91:526-529.
36. Sadlier D.M., Magee C.C. Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study. Clin Transplant 2007, 21:683-688.
37. Giannini S., Sella S. Silva Netto F, Cattelan C, Dalle Carbonare L, Lazzarin R, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res Apr 2010, 25(4):841-848.
38. Stavroulopoulos A., Cassidy M.J., Porter C.J., Hosking D.J., Roe S.D. Vitamin D status in renal transplant recipients. Am J Transplant 2007, 7:2546-2552.
39. Courbebaisse M., Thervet E., Souberbielle J.C., Zuber J., Eladari D., Martinez F., et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009, 75:646-651.
40. Jimenez Alvaro S., Marcen R., Villacorta J., Fernandez-Rodriguez A., Galeano C., Villafruela J.J., et al. Cholecalciferol supplements improve vitamin D deficiency in renal transplant recipients. Transplant Proc 2010, 42:2921-2923.
41. Evenepoel P., Claes K., Kuypers D.R., Debruyne F., Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007, 22:1730-1737.
42. Chou F.F., Hsieh K.C., Chen Y.T., Lee C.T. Parathyroidectomy followed by kidney transplantation can improve bone mineral density in patients with secondary hyperparathyroidism. Transplantation 2008, 86:554-557.
43. Serra A.L., Savoca R., Huber A.R., Hepp U., Delsignore A., Hersberger M., et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007, 22:577-583.
44. Serra A.L., Wuhrmann C., Wuthrich R.P. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis Dec 2008, 52(6):1151-1157.
45. White C.A., Huang D., Akbari A., Garland J., Knoll G.A. Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review. Am J Kidney Dis 2008, 51:1005-1015.
46. White C.A., Akbari A., Doucette S., Fergusson D., Hussain N., Dinh L., et al. Estimating GFR using serum beta trace protein: accuracy and validation in kidney transplant and pediatric populations. Kidney Int 2009, 76:784-791.